DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. - Momeny M; Tienhaara M; Sharma M; Chakroborty D; Varjus R; Takala I; Merisaari J; Padzik A; Vogt A; Paatero I; Elenius K; Laajala TD; et al. (EMBO molecular medicine, 2024)